The next-generation selective estrogen receptor degrader (SERD) camizestrant improved progression-free survival, compared with fulvestrant (Faslodex), in patients with hormone receptor-positive, HER2-negative breast cancer ...
Dec 8, 2022
0
0
In patients with hormone receptor (HR)-positive, HER2-negative tumors resistant to aromatase inhibitors, addition of the investigational AKT inhibitor capivasertib to fulvestrant (Faslodex) doubled the median progression-free ...
Dec 8, 2022
0
6
While it has long been recognized that drugs that block the cancer-promoting activity of estrogen reduce risk of developing new breast cancers, a new computer modeling study led by researchers at Georgetown Lombardi Comprehensive ...
Dec 1, 2022
0
2
Among women with early breast cancer who have aromatase inhibitor-related joint pain, pain at 52 weeks is reduced with true acupuncture (TA) compared with sham acupuncture (SA) or waiting-list control (WC), according to a ...
Nov 14, 2022
0
2
A new breast cancer test could detect women who are less likely to respond to a standard breast cancer treatment—and could help improve treatment for these women by giving them other treatment options earlier.
Nov 1, 2022
0
42
A new paper in the Journal of the National Cancer Institute, published by Oxford University Press, finds that menopausal hormone therapy for breast cancer survivors is not associated with breast cancer reoccurrence, despite ...
Jul 20, 2022
0
8
Probiotic bacteria may enhance anti-cancer activities of the breast cancer drug tamoxifen and other endocrine-targeted therapies, which could help reduce the risk of estrogen receptive positive (ER+) breast cancer, suggests ...
Jun 11, 2022
0
4
After examining 398 proteins, a University of Houston College of Pharmacy researcher has found one that is an important biomarker predicting therapy outcome and a potential drug target in estrogen receptor-positive (ER+) ...
Feb 21, 2022
0
54
A new study has shown that giving aromatase inhibitors instead of tamoxifen to premenopausal women with estrogen receptor positive (hormone-sensitive) breast cancer significantly reduces the risk of breast cancer recurrence. ...
Feb 3, 2022
0
67
Among patients with hormone receptor-positive breast cancer treated with an aromatase inhibitor plus palbociclib (Ibrance), those who displayed a rising ESR1 mutation detected in their blood before disease progression doubled ...
Dec 9, 2021
0
3
